Clinical Trial Update: A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight [Phase 3]

View source ↗

Summary

Phase 3 head-to-head trial comparing CagriSema with tirzepatide for obesity has completed, according to Novo Nordisk.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• CagriSema (cagrilintide/semaglutide)
• Tirzepatide (tirzepatide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Obesity | Phase 3 | Status: COMPLETED